Formulary
Patient education is vital to maximise the likelihood of success. Prescribers and pharmacists should ensure that patients are counselled appropriately.
| Helicobacter pylori eradication | ||||||||
|
Formulary
|
||||||||
The following information should be used in conjunction with NICE CG184 *In January 2024, the MHRA published a Drug Safety Update on fluoroquinolone antibiotics. These must now only be prescribed when other commonly recommended antibiotics are inappropriate. NICE is assessing the impact of this warning on recommendations in this guideline. All courses are 7 days.
|
||||||||
 MHRA: Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate MHRA: Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects NICE NG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
||||||||
|
Links
LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate
- MHRA: Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management